TEKTURNA
LOE Approachingaliskiren hemifumarate
NDAORALTABLET
Approved
Mar 2007
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
3
Data completeness
6/8 — Strong
TEKTURNA (aliskiren hemifumarate) is perfusion. Approved for hypertension in adults, greater, to lower blood pressure and 1 more indications. First approved in 2007.
Drug data last refreshed 4d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEKTURNA (aliskiren hemifumarate) is an oral direct renin inhibitor approved in 2007 for hypertension in adults. It uniquely blocks the first step of the renin-angiotensin-aldosterone system (RAAS) by preventing renin from converting angiotensinogen to angiotensin I, thereby reducing plasma renin activity and downstream vasoconstriction. The mechanism allows for effective blood pressure reduction whether used as monotherapy or in combination with other antihypertensive agents.
$0.001BPart D
LOE ApproachingDeclining
3mo to LOERapidly declining market presence with minimal Part D activity signals a shrinking commercial footprint and reduced need for field-facing roles.
Mechanism of Action
perfusion. Renin cleaves angiotensinogen to form the inactive decapeptide angiotensin I (Ang I). Ang I is converted to the active octapeptide angiotensin II (Ang II) by ACE and non-ACE pathways. Ang II is a powerful vasoconstrictor and leads to the release of catecholamines from the adrenal medulla…
Indications (4)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.